Blocking drug activation as a therapeutic strategy to attenuate acute toxicity and physiological effects of heroin

Ting Zhang¹,², Xirong Zheng¹,², Kyungbo Kim¹,², Fang Zheng¹,² & Chang-Guo Zhan¹,²

Heroin is a growing national crisis in America. There is an increasing frequency of heroin overdoses. All of the currently used therapeutic approaches to treatment of heroin abuse and other opioid drugs of abuse focus on antagonizing a brain receptor (particularly µ-opiate receptors). However, it has been known that the therapeutic use of certain µ-opiate receptor antagonist may actually increase heroin overdose. Once overdosed, heroin addicts may continue to get overdosed again and again until fatal. Here we report our design and validation of a novel therapeutic strategy targeting heroin activation based on our analysis of the chemical transformation and functional change of heroin in the body. An effective blocker of heroin activation, such as ethopropazine tested in this study, may be used as a standalone therapy or in combination with a currently available, traditional medications targeting µ-opiate receptors (e.g. naltrexone or its extended-release formulation Vivitrol). The combination therapy would be ideal for heroin abuse treatment as the effects of two therapeutic agents targeting two independent mechanisms are cooperative.
overdose treatment and extended-release naltrexone for relapse-preventing addiction treatment. All of these therapeutic agents in the current clinical use, and other therapeutic candidates under preclinical/clinical development, bind to µ-opiate receptors (and/or a related receptors) in the brain and block the physiological effects of heroin or another opioid used. The overdose treatment with naloxone appears to be effective, but the precondition is that the naloxone treatment can begin soon after a heroin overdose. For the problem, once overdosed, heroin addicts may continue to get overdosed again and again until fatal. Some heroin addicts survived from one overdose with treatment in hospital, and then died of another overdose the next day. Even worse, the use of naltrexone or its extended-release formulation Vivitrol actually increased heroin overdose. A truly effective heroin treatment should account for not only rescuing heroin addicts who have already been overdosed, but also preventing the addicts from overdose again.

Here we report our mechanism-based rational design and validation of a novel therapeutic strategy targeting heroin activation to complement the currently available antagonist approach. Our strategy is based on the fact that heroin itself is actually a prodrug which must be activated to be effective, and our further analysis of the chemical transformation and functional change of heroin in the body. An effective blocker of heroin activation may be used as a standalone therapy or in combination with one of the currently available traditional medications targeting µ-opiate receptors (e.g. naloxone or its extended-release formulation Vivitrol). The combination therapy would be ideal for heroin abuse treatment as the effects of two therapeutic agents targeting two independent mechanisms are perfectly cooperative.

Results
Catalytic parameters of the primary enzyme involved in heroin activation. It has been known that heroin (3,6-diacetylmorphine, synthesized from morphine) behaves as a prodrug and its effects are mediated by its metabolites (6-MAM and morphine depicted in Fig. 1) . Once administered, heroin is very rapidly metabolized by cholinesterases to 6-monoacetylmorphine (6-MAM) first, and then to morphine (see Fig. 1). Both 6-MAM and morphine are responsible for the toxic and physiological effects of heroin . In fact, heroin is at least 10-fold more toxic than morphine , but the binding affinity of heroin itself with the µ-opiate receptors is significantly lower than that of morphine. The most toxic metabolite is 6-monoacetylmorphine (6-MAM) which has the highest binding affinity with the µ-opiate receptors. 6-MAM (with a relatively shorter biological half-life compared to morphine) is mainly responsible for the acute toxicity whereas morphine (with a much longer biological half-life) is mainly responsible for the long-term toxicity, of heroin. So, cholinesterases are crucial enzymes that control the metabolic profile, and thus affect the toxic and physiological effects, of heroin.

There are two main cholinesterases, including acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Which cholinesterase (AChE or BChE) is mainly responsible for heroin hydrolysis has been controversial. It was once proposed that human erythrocyte AChE is responsible for hydrolyzing heroin. However, further studies by Lockridge et al. indicated that human serum BChE, instead of erythrocyte AChE, is responsible for hydrolyzing heroin. As previously reported catalytic parameters for BChE-catalyzed hydrolysis of heroin were inconsistent for heroin (3.6-diacetylmorphine, synthesized from morphine) behaves as a prodrug and its effects are mediated by its metabolites (6-MAM and morphine depicted in Fig. 1). Once administered, heroin is very rapidly metabolized by cholinesterases to 6-monoacetylmorphine (6-MAM) first, and then to morphine (see Fig. 1). Both 6-MAM and morphine are responsible for the toxic and physiological effects of heroin. In fact, heroin is at least 10-fold more toxic than morphine , but the binding affinity of heroin itself with the µ-opiate receptors is significantly lower than that of morphine. The most toxic metabolite is 6-monoacetylmorphine (6-MAM) which has the highest binding affinity with the µ-opiate receptors. 6-MAM (with a relatively shorter biological half-life compared to morphine) is mainly responsible for the acute toxicity whereas morphine (with a much longer biological half-life) is mainly responsible for the long-term toxicity, of heroin. So, cholinesterases are crucial enzymes that control the metabolic profile, and thus affect the toxic and physiological effects, of heroin.

Effects of ethopropazine on heroin-induced hyperactivity. Notably, many cholinesterase inhibitors have been approved by the FDA as therapeutic agents for treatment of Alzheimer’s disease (AD), myasthenia gravis, glaucoma, and Parkinson’s disease etc. Most of these cholinesterase inhibitors are able to inhibit both AChE and BChE, without the desirable high selectivity for BChE over AChE. Nevertheless, ethopropazine (a BChE inhibitor approved by the FDA for treatment of Parkinson’s disease) is highly selective for BChE over...
AChE, with IC₅₀ = 210–300 nM for BChE and IC₅₀ = 210 μM for AChE (~1000-fold selectivity)²⁴. So, ethopropazine was used to examine whether a BChE-selective inhibitor can really attenuate the toxic and physiological effects of heroin in mice. First, we determined the effects of ethopropazine on heroin-induced hyperactivity by performing locomotor activity tests in high density, non-porous plastic chambers measuring 50 cm (L) × 50 cm (W) × 38 cm (H) in a light- and sound-attenuating behavioral test enclosure (San Diego Instruments, San Diego, CA). As seen in Fig. 2, ethopropazine (10 mg/kg, IV) administration 10 min prior to the heroin (2.5 mg/kg, IP) injection significantly attenuated heroin-induced hyperactivity.

**Effects of ethopropazine on heroin-induced acute toxicity.** Ethopropazine was tested further for its effectiveness in protecting mice against heroin-induced acute toxicity. Heroin-induced acute toxicity was characterized by the lethality (occurrence of death). For the protection experiments, a single dose of ethopropazine was administrated (IV) prior to administration of a lethal dose (LD₁₀₀) of heroin (e.g. 25 mg/kg, IV). At 10 min after IV administration of ethopropazine or saline (negative control), the mice were given a lethal dose (LD₁₀₀) of heroin. The protection experiments were performed under various dose conditions (n = 6 for each scenario). Depicted in Fig. 3 are the data obtained from the protection experiments with ethopropazine (1 or 10 mg/kg, IV) and/or naltrexone (0.3 mg/kg, IV); we also tried to use a higher dose (1 mg/kg, IV) of naltrexone and noted that the IV dose of 1 mg/kg would be too high because the mice injected intravenously with 1 mg/kg naltrexone were not able to stand and could hardly move at all.

The data depicted in Fig. 3 reveal that, without ethopropazine or naltrexone administration, all mice died within 2 min after the heroin injection (25 mg/kg, IV). However, pre-treatment of mice with ethopropazine (10 mg/kg, IV) 10 min before the heroin injection protected all mice against the acute toxicity of a lethal dose of heroin.

---

**Figure 2.** (A) Plot of measured initial reaction rates (represented in nM min⁻¹ per nM enzyme, or min⁻¹, at 37°C, measured in triplicate, with error bars in standard deviations) versus the substrate (heroin) concentration for recombinant human BChE-catalyzed hydrolysis of heroin. (B) Locomotor activity in mice expressed as total distance traveled (in centimeters) per min after heroin injection (2.5 mg/kg, IP) or saline, with or without ethopropazine injection (10 mg/kg, IV) 10 min prior to the heroin (or nothing) injection (2.5 mg/kg, IP) at the time 0. A group of eight mice (n = 8) were used at the same time for each dose condition.
heroin (25 mg/kg, IV). So, 10 mg/kg ethopropazine was able to protect all of the mice from the heroin-induced lethality (full protection).

Further, we also tested whether Galantamine (a highly potent and selective inhibitor of AChE, approved by the FDA for treatment of Alzheimer’s disease) can also attenuate heroin-induced toxicity, and found that pre-treatment of mice with Galantamine at a dose of 10 or 5 mg/kg (IV or IP) before the heroin injection did not protect any mouse against the acute toxicity of a lethal dose of heroin (25 mg/kg, IV), which is consistent with the concept that BChE, rather than AChE, is the primary heroin-activating enzyme.

Additional data in Fig. 3 indicate that 1 mg/kg ethopropazine or 0.3 mg/kg naltrexone only provided partial protection, but the combined use of 0.3 mg/kg naltrexone and 1 mg/kg ethopropazine provided the full protection. So, the protection effects of ethopropazine and naltrexone are indeed cooperative, as expected.

Discussion
All of the animal data obtained consistently support the concept of using a potent BChE-selective inhibitor, such as ethopropazine tested in this study, as a blocker of heroin activation to attenuate the toxicity and physiological effects of heroin. For this reason, ethopropazine may be repurposed for clinical use to attenuate the acute toxicity of heroin.

Further, although a heroin activation blocker, such as ethopropazine which we have identified in this study for the first time, may be used as a standalone therapy for heroin addiction treatment, the combined use of a heroin activation blocker and a μ-opiate receptor antagonist should be more effective. This is because the two mechanisms are independent and, therefore, their effects can be perfectly cooperative (Bliss Independence model)\(^\text{25,26}\). The cooperative effects of the two therapeutic agents should be much more effective. For example, if a heroin activation blocker with a given concentration in plasma can block heroin activation by 90% and if the μ-opiate receptor antagonist with a given concentration in the brain can block the receptors binding with the available active heroin metabolites (associated with 10% of the total heroin) also by 90%, then only 10% of the 10% (i.e. 1% of the total) can bind with μ-opiate receptors. Thus, the two types of therapeutic agents together can block the toxicity and physiological effects of heroin by 99%, when each one can block the toxicity and physiological effects of heroin by 90%. For the same logics, the two types of therapeutic agents together can block the toxicity and physiological effects of heroin by 75%, when each one can block them by 50%; the two types of therapeutic agents together can block the toxicity and physiological effects of heroin by 99.99%, when each one can block them by 99%. So, the novel combination therapy is potentially more promising for heroin addiction treatment and for prevention of heroin overdose. In addition, the general concept of a combination therapy with two therapeutic agents (e.g. ethopropazine combined with naltrexone or its extended-release formulation Vivitrol) targeting two independent mechanisms may also be useful for therapeutic treatment of other drugs of abuse.

Materials and Methods

Materials. The purified recombinant human BChE protein was prepared in our previous study\(^\text{27}\). Briefly, the BChE protein was expressed in CHO-S cells, and the secreted enzyme in the culture medium was purified by a two-step approach, including ion exchange chromatography using QFF anion exchanger and affinity chromatography using procainamide-sepharose. The purified protein was stored at −80°C before the use. Heroin and its metabolite 6-MAM were provided by the National Institute on Drug Abuse (NIDA) Drug Supply Program (Bethesda, MD). All other supplies (including ethopropazine and naltrexone) were purchased from Sigma-Aldrich (St. Louis, MO).

Animals. Male CD-1 mice (28–32 g) were ordered from Harlan (Harlan, Indianapolis, IN), and housed in cage. All mice were allowed ad libitum access to food and water and maintained on a 12 h light/12 h dark cycle, with the lights on at 8:00 a.m. at a room temperature of 21–22°C. Experiments were performed in a same colony room in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the National Institutes of Health. The animal protocol was approved by the IACUC (Institutional Animal Care and Use Committee) at the University of Kentucky.
In vitro enzyme activity assay. For kinetic analysis of the catalytic activity of BChE against heroin, the purified enzyme and heroin were incubated in 0.1 M phosphate buffer, pH 7.4, at 37 °C. The enzymatic reaction was terminated and the protein was precipitated by adding 100 μl of iced 50% acetonitrile/0.5 M hydrochloric acid, followed by 5 min centrifugation at 15,000 g. The resulting supernatant was subjected to reverse-phase HPLC (RP-HPLC) on a 5 μm C18 110 Å column (250 × 4.6 mm; Gemini) and RP-HPLC was performed using the mobile phase consisting of 20% acetonitrile in 0.1% TFA. The remaining substrate (heroin) and the formed reaction product (6-MAM) were monitored by a fluorescence detector with an excitation wavelength of 230 nm and emission wavelength of 315 nm and by monitoring UV absorbance at 230 nm. The quantification was based on a standard curve prepared using an authentic standard compound. The measurement was performed in triplicate, and the catalytic parameters were determined by using the Michaelis-Menten kinetic equation.

Locomotor activity assay. To determine the effects of ethopropazine on heroin-induced hyperactivity, locomotor activity tests were performed in high density, non-porous plastic chambers measuring 50 cm (L) × 50 cm (W) × 38 cm (H) in a light- and sound- attenuating behavioral test enclosure (San Diego Instruments, San Diego, CA). This system available in our lab can test 8 mice at the same time. Cumulative distance traveled and speed were recorded by EthoVision XT video tracking system (Noldus Information Technology, Wageningen, Netherlands) to represent the locomotor activity. Mice were introduced to the test chambers for one habituation session (no injection). Before the test session, mice were allowed to acclimate to the test chambers for at least 60 minutes, and the total distance traveled during this period of time were determine the basal activity. Then, ethopropazine or saline (negative control) was administered through intravenous (IV) injection. At 10 min after the ethopropazine or saline injection, the mice were given a pharmacological dose of heroin (e.g., 2.5 mg/kg, IP). After the heroin administration, mice were immediately returned to the test chamber for a 60-minute session of activity monitoring.

Protection study in mice. Heroin-induced acute toxicity was characterized in this study by the occurrence of death. Protection experiment was performed by pretreatment of mice with ethopropazine (1 or 10 mg/kg, IV) and/or naltrexone (0.3 mg/kg) 10 min before administration of heroin (25 mg/kg, IV). Following the heroin administration, mice were immediately placed in containers for observation. The presence or absence of death was recorded for 6 hours following heroin administration.

References
1. Drash, W. & Blau, M. CNN Front Page News - In America’s drug death capital: How heroin is scaring the next generation, (http://www.cnn.com/2016/09/16/health/huntington-heroin/index.html) 5:45 PM ET, Fri., September 16, 2016 (last seen: December 2017).
2. USDOS. CD No. 2 (“1. Chasing the Dragon; 2. Heroin Hurts; 3. Heroin is Hell; 4. Heroin is Here; 5. Heroin’s Hold”), distributed to the invited attendees of US Attorney-General Loretta E. Lynch’s “National Heroin & Opioid Awareness Week” policy speech at College of Pharmacy, University of Kentucky on September 20, 2016 (2016).
3. ONDCP. Prescription Drug Monitoring Programs, (https://obamawhitehouse.archives.gov/sites/default/files/ondcp/Fact_Sheets/pdmp_fact_sheet_4_8-11.pdf) April 2011 (last seen: December 2017) (2011).
4. WLKY. Study shows prescription drug abuse declining in Kentucky, (http://www.wlky.com/news/study-shows-prescription-drug-abuse-declining-in-kentucky/34380884), and the comments on the report. 4:31 PM EDT Jul 27, 2015 (last seen: December 2017) (2015).
5. USDOS. CD No.1 (“CD of Heroin Facts and Other Documents”), distributed to the invited attendees of US Attorney-General Loretta E. Lynch’s “National Heroin & Opioid Awareness Week” policy speech at College of Pharmacy, University of Kentucky on September 20, 2016 (2016).
6. Krieter, P. et al. Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose. J. Clin. Pharmacol. 56, 1243–1253 (2016).
7. Zaaijer, E. R., Goudriaan, A. E., Koeter, M. W., Bovii, J. & van den Brink, W. Acceptability of Extended-Release Naltrexone by Heroin-Dependent Patients and Addiction Treatment Providers in the Netherlands. Subst. Use Misuse 51, 1905–1911 (2016).
8. Ritter, A. J. Naltrexone in the treatment of heroin dependence: relationship with depression and risk of overdose. Australian and New Zealand Journal of Psychiatry 36, 224–228 (2002).
9. SAMHSA. The Facts about Naltrexone for Treatment of Opioid Addiction, (http://store.samhsa.gov/shin/content//SMA12-4444 pdmp_fact_sheet_4-8-11.pdf) (2011).
10. Gibson, A. & Degenhardt, L. Mortality related to naltrexone in the treatment of opioid dependence: A comparative analysis, (https://ndarc.med.unsw.edu.au/resource/mortality-related-naltrexone-treatment-opioid-dependence-comparative-analysis) NDARC Technical Report No. 229 (2005).
11. Inturrisi, C. E. et al. Evidence from opiate binding studies that heroin acts through its metabolites. Life Sci. 33(Suppl. 1), 773–776 (1983).
12. Strandberg, J. et al. Toxicological analysis in rats subjected to heroin and morphine overdose. Toxicol. Lett. 166, 11–18 (2006).
13. Lockridge, O., Mattershaw-Jackson, N., Eckerson, H. W. & LaDu, B. N. Hydrolysis of diacetylmorphine (heroin) by human serum cholinesterase. J. Pharmacol. Exp. Ther. 215, 1–8 (1980).
14. Eddy, N. B. & Howes, H. A. Studies of morphine, codeine and their derivatives VIII Monooxyl- and diacetylmorphine their hydrogenated derivatives. J. Pharmacol. Exp. Ther. 53, 430–439 (1935).
15. Wright, C. I. & Barbour, F. A. The respiratory effects of morphine, codeine and related substances IV. The effect of alpha-monooxylmorphine, monooxyldihydromorphine, diacetylmorphine (heroin) and diacetyldihydromorphine on the respiratory activity of the rabbit. J. Pharmacol. Exp. Ther. 54, 25–33 (1935).
16. Selley, D. E. et al. mu-Opioid receptor-mediated G-protein activation by heroin metabolites: evidence for greater efficacy of 6-monooxylmorphine compared with morphine. Biochem. Pharmacol. 62, 447–455 (2001).
17. Andersen, J. M., Ripel, A., Boix, F., Normann, P. T. & Morland, J. Increased locomotor activity induced by heroin in mice: pharmacokinetic demonstration of heroin as a pro-drug for the mediator, 6-monooxylmorphine, in vivo. J. Pharmacol. Exp. Ther. 331, 153–161 (2009).
18. Boix, F., Andersen, J. M. & Morland, J. Pharmacokinetic modeling of subcutaneous heroin and its metabolites in blood and brain of mice. Addict. Biol. 18, 1–7 (2013).
19. NIDA. DrugFacts: Heroin, (http://www.drugabuse.gov/publications/drugfacts/heroin) (2015).
20. Wikipedia, http://en.wikipedia.org/wiki/Morphine#cite_note-urlDrugFacts__Heroin___7C_National_Institute_on_Drug_Abuse_28NIDA.29-23 (last seen: March 6, 2018) (2018).
21. Smith, D. A. & Cole, W. J. Identification of an arylesterase as the enzyme hydrolysing diacetylmorphine (heroin) in human plasma. *Biochem. Pharmacol.* **25**, 367–370 (1976).

22. Salmon, A. Y., Goren, Z., Avissar, Y. & Soreq, H. Human erythrocyte but not brain acetylcholinesterase hydrolys heroin to morphine. *Clinical and Experimental Pharmacology and Physiology* **26**, 596–600 (1999).

23. Kamendulis, L. M., Brzezinski, M. R., Pindel, E. V., Bosron, W. F. & Dean, R. A. Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases. *Journal of Pharmacology and Experimental Therapeutics* **279**, 713–717 (1996).

24. Atack, O. A., Vu, Q.-S., Soncrant, T. T., Brossi, A. & Rapoport, S. I. Comparative Inhibitory Effects of Various Physostigmine Analogs against Acetyl- and Butyrylcholinesterases, *J. Pharm. Exp. Therap.* **249**, 194–202 (1989).

25. Bliss, C. I. The calculation of microbial assays. *Bacteriol. Rev.* **20**, 243–258 (1956).

26. Bliss, C. I. The toxicity of poisons applied jointly. *Ann. Appl. Biol.* **26**, 585–615 (1939).

27. Chen, X. et al. Kinetic characterization of a cocaine hydrolase engineered from mouse butyrylcholinesterase. *Biochem. J.* **466**, 243–251 (2015).

**Acknowledgements**

This work was supported in part by the National Institutes of Health (NIH grants UH2/UH3 DA041115, R01 DA035552, R01 DA032910, R01 DA013930, and R01 DA025100).

**Author Contributions**

T.Z. and X.Z. performed *in vivo* studies and analyzed the data. K.K. carried out the *in vitro* assay. F.Z. and C.-G.Z. designed the study, analyzed the data, and finalized the manuscript.

**Additional Information**

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018